Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

NCT06910657 is registered in ClinicalTrials.gov with ViroMissile, Inc. as lead sponsor.

NCT NCT06910657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06910657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors
Lead sponsor
ViroMissile, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 25, 2025
Completion date
May 31, 2027
Enrollment
78 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal gland tumors, bladder cancer, breast cancer, cervical cancers, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancers, hepatocellular carcinoma, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, sarcoma